Scientists Test Early Intervention Strategy to Fight Pancreatic Tumours

Researchers are targeting pancreatic cancer using a strategy called cancer interception, which aims to treat abnormal tissues before they turn into dangerous tumours. This new approach was a key topic at the American Association for Cancer Research Conference on Pancreatic Cancer held in San Diego, California. The meeting followed the US Food and Drug Administration's approval of the drug daraxonrasib, also known as Rasonque, in August. Experts believe combining such drugs with early-detection tools could significantly improve survival rates. Diane Simeone, director of the Moores Cancer Center at University of California San Diego Health, stated at the meeting that interception could potentially lift the five-year survival rate from 13.7% to over 50%. Anirban Maitra, director of the Perlmutter Cancer Center at New York University Langone Health, also expressed optimism about the current progress. Pancreatic tumours are typically hard to treat because they grow fast, resist most therapies, and wrap around major blood vessels. Even so, catching the disease early allows five-year survival rates to exceed 80%. Because early symptoms are vague, more than half of patients are diagnosed only after the cancer spreads to other organs. To catch the disease earlier, Simeone and her team launched a clinical study named PRECEDE. The study aims to follow 20,000 people who have a family history of the disease, genetic risk factors, or abnormal pancreatic growths. So far, the team has enrolled over 12,000 participants and diagnosed more than 50 cases, many at early stages. The PRECEDE team plans to test experimental blood tests and use artificial intelligence to spot abnormalities on scans before they are visible to the naked eye. Researchers also want to test whether drugs like daraxonrasib can help patients when given right after surgery for early-stage growths. Meanwhile, Ben Stanger, a cancer researcher at the University of Pennsylvania in Philadelphia, tested similar drugs on mice with cancer-linked Kras gene mutations and found that the treatment improved survival in the animals.

Context

Pancreatic cancer is widely considered one of the hardest malignancies to treat because symptoms often appear only after the disease has advanced. Clinical studies like PRECEDE rely on tracking high-risk individuals over long periods to catch abnormal growths before they become life-threatening. Medical researchers hope that combining early detection with targeted drug treatments will finally shift survival statistics that have remained largely unchanged for decades.